ERBB2 and gastric adenocarcinoma: The phase III KEYNOTE‐811 trial compared pembrolizumab versus placebo in combination with trastuzumab and chemotherapy (fluorouracil and cisplatin, or capecitabine and oxaliplatin) in previously untreated HER2‐positive advanced gastric adenocarcinoma.